245 related articles for article (PubMed ID: 33386541)
1. Landmark Series: Immunotherapy and Targeted Therapy for Pancreatic Cancer.
Rocha FG
Ann Surg Oncol; 2021 Mar; 28(3):1400-1406. PubMed ID: 33386541
[TBL] [Abstract][Full Text] [Related]
2. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
4. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies in the treatment of pancreatic cancer.
Huang ZQ; Buchsbaum DJ
Immunotherapy; 2009 Mar; 1(2):223-9. PubMed ID: 20046965
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Mosquera C; Maglic D; Zervos EE
Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
[TBL] [Abstract][Full Text] [Related]
9. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
Cervera P; Fléjou JF
Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for pancreatic cancer: A long and hopeful journey.
Xu JW; Wang L; Cheng YG; Zhang GY; Hu SY; Zhou B; Zhan HX
Cancer Lett; 2018 Jul; 425():143-151. PubMed ID: 29605510
[TBL] [Abstract][Full Text] [Related]
11. Antibody therapy in pancreatic cancer: mAb-ye we're onto something?
Boland AJ; O'Kane AA; Buick R; Longley DB; Scott CJ
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188557. PubMed ID: 33945846
[TBL] [Abstract][Full Text] [Related]
12. Modern Immunotherapy for the Treatment of Advanced Gastrointestinal Cancers.
Khalil DN; Segal NH
Oncology (Williston Park); 2016 Jan; 30(1):85-90, 93. PubMed ID: 26791849
[TBL] [Abstract][Full Text] [Related]
13. Translation of recent advances and discoveries in molecular biology and immunology in the diagnosis and treatment of pancreatic cancer.
Albo D; Farrow B; Berger DH
Surg Oncol Clin N Am; 2008 Apr; 17(2):357-76, ix. PubMed ID: 18375357
[TBL] [Abstract][Full Text] [Related]
14. Current and Emerging Targeting Strategies for Treatment of Pancreatic Cancer.
Baines AT; Martin PM; Rorie CJ
Prog Mol Biol Transl Sci; 2016; 144():277-320. PubMed ID: 27865460
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors in the Treatment of Gastrointestinal Malignancies: A Review of Current and Future Therapies.
Hsu A; Mendelson L; Almhanna K
R I Med J (2013); 2020 Apr; 103(3):33-37. PubMed ID: 32236159
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
Cheung PF; Lutz M; Siveke JT
Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Expression in Pancreatic Cancer.
Zheng L
J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131993
[No Abstract] [Full Text] [Related]
18. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
19. [Update on the treatment of common gastrointestinal malignancies].
Wolf I; Catane R; Symon Z; Papa MZ; Fider HH
Harefuah; 2005 Jan; 144(1):39-44, 70. PubMed ID: 15719821
[TBL] [Abstract][Full Text] [Related]
20. Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies.
Halfdanarson TR; Strosberg JR
Curr Clin Pharmacol; 2015; 10(4):305-10. PubMed ID: 26548907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
